TY - JOUR
T1 - Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity
AU - Boudreau, Matthew W.
AU - Hergenrother, Paul J.
N1 - We would like to thank the University of Illinois Library services for their help in finding literature from the late 18th and early 19th century. For funding this work, we would like to thank the NIH (CA258746), and we extend our gratitude to the University of Illinois and the Cancer Center at Illinois (CCIL). M. W. B. is a member of the NIH Chemistry-Biology Interface Training Program (T32-GM136629), was an ACS Medicinal Chemistry Predoctoral Fellow, and he is supported by an NCI F99/K00 predoctoral fellowship (F99-CA253731; K00-CA253731).
PY - 2022/5/9
Y1 - 2022/5/9
N2 - Development of targeted anticancer modalities has prompted a new era in cancer treatment that is notably different from the age of radical surgery and highly toxic chemotherapy. Behind each effective compound is a rich and complex history from first identification of chemical matter, detailed optimization, and mechanistic investigations, ultimately leading to exciting molecules for drug development. Herein we review the history and on-going journey of one such anticancer scaffold, the 3-(4-hydroxyphenyl)indoline-2-ones. With humble beginnings in 19th century Bavaria, we review this scaffold's synthetic history and anticancer optimization, including its recent demonstration of tumor eradication of drug-resistant, estrogen receptor-positive breast cancer. Compounds containing the 3-(4-hydroxyphenyl)indoline-2-one pharmacophore are emerging as intriguing candidates for the treatment of cancer.
AB - Development of targeted anticancer modalities has prompted a new era in cancer treatment that is notably different from the age of radical surgery and highly toxic chemotherapy. Behind each effective compound is a rich and complex history from first identification of chemical matter, detailed optimization, and mechanistic investigations, ultimately leading to exciting molecules for drug development. Herein we review the history and on-going journey of one such anticancer scaffold, the 3-(4-hydroxyphenyl)indoline-2-ones. With humble beginnings in 19th century Bavaria, we review this scaffold's synthetic history and anticancer optimization, including its recent demonstration of tumor eradication of drug-resistant, estrogen receptor-positive breast cancer. Compounds containing the 3-(4-hydroxyphenyl)indoline-2-one pharmacophore are emerging as intriguing candidates for the treatment of cancer.
UR - http://www.scopus.com/inward/record.url?scp=85133725419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133725419&partnerID=8YFLogxK
U2 - 10.1039/d2md00110a
DO - 10.1039/d2md00110a
M3 - Review article
C2 - 35814932
AN - SCOPUS:85133725419
SN - 2632-8682
VL - 13
SP - 711
EP - 725
JO - RSC Medicinal Chemistry
JF - RSC Medicinal Chemistry
IS - 6
ER -